The global extended release drugs market is experiencing significant growth, projected to expand at a robust 11% CAGR from 2022 to 2032. With a valuation of USD 48 billion in 2022, the market is ...
The Print on MSN8d
How reciprocal Trump tariffs may impact Indian pharma, and become a bitter pill for the USSpooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
Irish Examiner on MSN19h
Trump's tariff threat on Irish pharma sector puts €44bn exports at 'considerable risk'Tariffs drive inflation, negatively impacting consumers on both sides of the Atlantic. Increased protectionism is in nobody’s ...
In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...
B.C. government B.C. Supreme Court opioid case against pharmaceutical companies can move ahead, appeal court rules in ...
India with its vast pharmaceutical and chemical industries is an emerging source for fentanyl precursor chemicals. Mexican ...
SMi Reports: Alie Jahangir from Janssen Pharmaceutical to speak at Pre-Filled ... Manufacturers need to eliminate the interaction between drugs and packaging materials. Regulatory bodies companies ...
The U.S. Department of Health and Human Services (HHS) made its initial offers to pharmaceutical companies pursuant to the IRA in February 2024. The drugs initially selected for the price ...
While there are plenty of EGFR-targeting drugs on the market for NSCLC, Rybrevant is the first to be FDA-approved for patients with exon 20 mutations, and also represents Janssen's first lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback